These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 22354221)

  • 21. Severe acute interstitial lung disease induced by crizotinib therapy in a patient with c-Met amplification non-small cell lung cancer.
    Ji Y; Zhang Z; Nie K; Lan K; Geng C; Liu S; Zhang L; Zhang Z; Sun L; Zou X
    Chin Med J (Engl); 2014; 127(8):1600. PubMed ID: 24762619
    [No Abstract]   [Full Text] [Related]  

  • 22. Resistance: Crizotinib makes a comeback.
    Shipman L
    Nat Rev Cancer; 2016 Feb; 16(2):69. PubMed ID: 26797648
    [No Abstract]   [Full Text] [Related]  

  • 23. Crizotinib Resensitization by Compound Mutation.
    Shaw AT; Engelman JA
    N Engl J Med; 2016 May; 374(18):1790-1. PubMed ID: 27144862
    [No Abstract]   [Full Text] [Related]  

  • 24. Crizotinib Resensitization by Compound Mutation.
    Bordi P; Del Re M; Tiseo M
    N Engl J Med; 2016 May; 374(18):1790. PubMed ID: 27144863
    [No Abstract]   [Full Text] [Related]  

  • 25. Acute kidney injury following crizotinib administration for non-small-cell lung carcinoma.
    Gastaud L; Ambrosetti D; Otto J; Marquette CH; Coutts M; Hofman P; Esnault V; Favre G
    Lung Cancer; 2013 Nov; 82(2):362-4. PubMed ID: 24001942
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful crizotinib rechallenge after crizotinib-induced interstitial lung disease.
    Tachihara M; Kobayashi K; Ishikawa Y; Hori S; Tamura D; Otera H; Funada Y; Nishimura Y
    Jpn J Clin Oncol; 2014 Aug; 44(8):762-4. PubMed ID: 24872405
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Non-Small Cell Lung Cancer Patient.
    Remon J; Gazzah A; Besse B; Soria JC
    J Thorac Oncol; 2015 Aug; 10(8):e72-3. PubMed ID: 26200282
    [No Abstract]   [Full Text] [Related]  

  • 28. ROS1--targeting the one percent in lung cancer.
    Gold KA
    N Engl J Med; 2014 Nov; 371(21):2030-1. PubMed ID: 25409376
    [No Abstract]   [Full Text] [Related]  

  • 29. Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go.
    Patel JD; Pasche B; Argiris A
    Crit Rev Oncol Hematol; 2004 Jun; 50(3):175-86. PubMed ID: 15182824
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multitargeted receptor tyrosine kinase inhibition: an antiangiogenic strategy in non-small cell lung cancer.
    Socinski MA
    Cancer Treat Rev; 2011 Dec; 37(8):611-7. PubMed ID: 21641723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increases in serum CYFRA21-1 concentration during successful treatment with crizotinib.
    Kanaji N; Tadokoro A; Watanabe N; Inoue T; Ishii T; Dobashi H; Bandoh S
    Am J Case Rep; 2014 Nov; 15():480-4. PubMed ID: 25380070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Crizotinib.
    Prescrire Int; 2013 Nov; 22(143):264. PubMed ID: 24427836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer-drug discovery--let's get ready for the next period.
    Longo DL
    N Engl J Med; 2014 Dec; 371(23):2227-8. PubMed ID: 25470699
    [No Abstract]   [Full Text] [Related]  

  • 34. Esophageal Ulcer in a Lung Cancer Patient. Crizotinib-induced Esophageal Injury.
    Sawada T; Maeno K; Joh T
    Gastroenterology; 2015 Aug; 149(2):e6-7. PubMed ID: 26123560
    [No Abstract]   [Full Text] [Related]  

  • 35. New Drug Treats forms of Non-Small Cell Lung Cancer and Thyroid Cancer.
    Aschenbrenner DS
    Am J Nurs; 2020 Sep; 120(9):25. PubMed ID: 32858693
    [No Abstract]   [Full Text] [Related]  

  • 36. [A new target in non-small cell lung cancer: ROS1 fusion gene].
    Cai WJ; Su B
    Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):1-4. PubMed ID: 23648291
    [No Abstract]   [Full Text] [Related]  

  • 37. Novel molecular trends in the management of advanced non-small-cell lung cancer.
    Metro G; Crinò L
    Expert Rev Anticancer Ther; 2012 Jun; 12(6):729-32. PubMed ID: 22716489
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization--why, when, and how?
    Dziadziuszko R; Hirsch FR; Varella-Garcia M; Bunn PA
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4409s-4415s. PubMed ID: 16857819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SRC inhibitors.
    Dy G
    J Thorac Oncol; 2010 Dec; 5(12 Suppl 6):S466-7. PubMed ID: 21102241
    [No Abstract]   [Full Text] [Related]  

  • 40. EGFR-directed therapies to treat non-small-cell lung cancer.
    Ho C; Laskin J
    Expert Opin Investig Drugs; 2009 Aug; 18(8):1133-45. PubMed ID: 19572809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.